FDA Approves Vimseltinib for Tenosynovial Giant Cell Tumors

The US Food and Drug Administration has approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC) to treat adult patients with symptomatic tenosynovial giant cell tumors (TGCT) who will not benefit from surgical resection.  The colony-stimulating factor 1 receptor (CSF1R) blocker joins another one already on the US market for the indication…